First Time Loading...

NanJing Pharmaceutical Co Ltd
SSE:600713

Watchlist Manager
NanJing Pharmaceutical Co Ltd Logo
NanJing Pharmaceutical Co Ltd
SSE:600713
Watchlist
Price: 4.9 CNY 0.41% Market Closed
Updated: May 17, 2024

Net Margin
NanJing Pharmaceutical Co Ltd

1.1%
Current
1%
Average
2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
1.1%
=
Net Income
587.8m
/
Revenue
53.5B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
CN
NanJing Pharmaceutical Co Ltd
SSE:600713
6.3B CNY
1%
US
Mckesson Corp
NYSE:MCK
73.4B USD
1%
US
Cencora Inc
NYSE:COR
44.3B USD
1%
US
Amerisourcebergen Corp
NYSE:ABC
35.4B USD
1%
US
Cardinal Health Inc
NYSE:CAH
24.2B USD
0%
US
Henry Schein Inc
NASDAQ:HSIC
9.6B USD
3%
KR
Celltrion Healthcare Co Ltd
KOSDAQ:091990
12.2T KRW
7%
CN
Sinopharm Group Co Ltd
HKEX:1099
68.5B HKD
2%
IT
Amplifon SpA
MIL:AMP
7.8B EUR
7%
CN
Huadong Medicine Co Ltd
SZSE:000963
58.2B CNY
7%
CN
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
52.6B CNY
1%
NanJing Pharmaceutical Co Ltd
SSE:600713
Country CN
Market Cap 6.3B CNY
Net Margin
1%
Mckesson Corp
NYSE:MCK
Country US
Market Cap 73.4B USD
Net Margin
1%
Cencora Inc
NYSE:COR
Country US
Market Cap 44.3B USD
Net Margin
1%
Amerisourcebergen Corp
NYSE:ABC
Country US
Market Cap 35.4B USD
Net Margin
1%
Cardinal Health Inc
NYSE:CAH
Country US
Market Cap 24.2B USD
Net Margin
0%
Henry Schein Inc
NASDAQ:HSIC
Country US
Market Cap 9.6B USD
Net Margin
3%
C
Celltrion Healthcare Co Ltd
KOSDAQ:091990
Country KR
Market Cap 12.2T KRW
Net Margin
7%
Sinopharm Group Co Ltd
HKEX:1099
Country CN
Market Cap 68.5B HKD
Net Margin
2%
Amplifon SpA
MIL:AMP
Country IT
Market Cap 7.8B EUR
Net Margin
7%
Huadong Medicine Co Ltd
SZSE:000963
Country CN
Market Cap 58.2B CNY
Net Margin
7%
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Country CN
Market Cap 52.6B CNY
Net Margin
1%

Profitability Report

View the profitability report to see the full profitability analysis for NanJing Pharmaceutical Co Ltd.

Full Profitability Report

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
1.1%
=
Net Income
587.8m
/
Revenue
53.5B
What is the Net Margin of NanJing Pharmaceutical Co Ltd?

Based on NanJing Pharmaceutical Co Ltd's most recent financial statements, the company has Net Margin of 1.1%.

ALPHA SPREAD
Join more than 138,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.